Ibrutinib in CLL/SLL: From bench to bedside (Review)
| Autor: | Qingzhi Shi, Li Yu, Jing Cheng, Fuming Zi, Aiping Tang |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Cancer Research Follicular lymphoma 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Piperidines immune system diseases Chemoimmunotherapy hemic and lymphatic diseases medicine Bruton's tyrosine kinase Animals Humans biology business.industry Adenine Waldenstrom macroglobulinemia General Medicine medicine.disease Leukemia Lymphocytic Chronic B-Cell Lymphoma 030104 developmental biology Pyrimidines Oncology chemistry 030220 oncology & carcinogenesis Ibrutinib biology.protein Cancer research Pyrazoles Mantle cell lymphoma Refractory Chronic Lymphocytic Leukemia business Signal Transduction |
| Zdroj: | Oncology reports. 42(6) |
| ISSN: | 1791-2431 |
| Popis: | B-cell receptor (BCR) signaling is important for the development and maturation of normal B-cells and plays a key role in B-cell malignancies. Bruton's tyrosine kinase (BTK), a crucial terminal kinase enzyme in BCR signaling, has emerged as an attractive target and has been successfully applied in the treatment of hematological malignancies. Ibrutinib, a BTK inhibitor, has demonstrated marked efficacy and tolerability in treatment-naive, relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL). Ibrutinib has been approved by the Food and Drug Administration (FDA) for the treatment of CLL/SLL, MCL, marginal zone lymphoma and Waldenstrom macroglobulinemia and by the China FDA for the treatment of CLL/SLL and MCL. Clinical trials of ibrutinib, as a single agent or combined with chemoimmunotherapy and other promising novel agents in the treatment of B-cell malignancy therapy, such as diffuse large B-cell lymphoma, follicular lymphoma, multiple myeloma, primary and secondary CNS lymphoma and acute lymphoblastic leukemia, T-cell lymphoma and myelodysplastic syndrome, are ongoing (https://clinicaltrials.gov/). The aim of the present review was mainly to cover the clinical developments regarding the use of ibrutinib in the treatment of CLL/SLL, as well as its safety and toxicity profile. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|